Scientists at the Weizmann Institute of Science have discovered immune memory cells capable of recognizing ovarian cancer and producing antibodies against tumor cells.
The finding could open new directions for the development of cancer vaccines and personalized immunotherapy. The research was conducted in the laboratory of Prof. Ziv Shulman and published in the scientific journal Immunity. Weizmann Institute of Science
Our immune system has a remarkable ability to remember previous infections. After encountering a virus or bacterium, some B cells become memory cells. They can remain in the body for years and respond rapidly if the same threat appears again.
Scientists have long been interested in whether a similar form of immune memory could exist against cancer.
The Israeli researchers examined tumor samples and nearby lymph nodes from 11 patients with high-grade serous ovarian cancer (HGSOC), the most common type of ovarian cancer.
They discovered memory B cells containing the genetic instructions necessary to produce antibodies capable of recognizing tumor cells.
Researchers recreated these antibodies in the laboratory and found that more than one-third bound strongly to ovarian cancer cells. Importantly, their binding to non-cancerous cells was significantly weaker, suggesting that the immune response was directed preferentially toward the tumor. Weizmann Institute of Science
Why Is This Discovery Important?
One of the biggest challenges in oncology is preventing cancer from returning after successful treatment.
If scientists can learn how to activate or strengthen immune memory against specific tumor cells, it may eventually become possible to develop therapeutic vaccines that teach the immune system to recognize cancer and respond more effectively if malignant cells reappear.
This concept differs from conventional vaccination. Instead of preventing an infectious disease, a therapeutic cancer vaccine would attempt to stimulate a patient's own immune system to identify and attack cancer cells.
The discovery may therefore contribute to future strategies aimed at preventing recurrence and improving immunotherapy.
However, the research remains at an early stage. The discovery of cancer-specific memory B cells does not mean that an ovarian cancer vaccine is currently available. Additional studies will be needed to determine how these cells can be safely activated and whether the immune response can produce meaningful clinical benefits.
Nevertheless, the study provides important evidence that the immune system is capable of developing a long-term memory response against cancer.
If you are looking for ovarian cancer treatment, a second medical opinion, or consultation with an Israeli oncologist, contact Sapir Medical Clinic. Our team can help organize consultations with Israeli specialists, review medical records, arrange molecular and diagnostic testing, and coordinate treatment in Israel.